Drug Trial Radar · NCT06661733
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Nov 18, 2024
Primary completion
Dec 23, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AZD5462 in participants with impaired renal function.
Conditions
- Renal Impairment
Interventions
AZD5462Drug
Participants will receive AZD5462 orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: Day 1 to Day 4
- Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 to Day 4
- Time to reach maximum observed plasma concentration (tmax)Time frame: Day 1 to Day 4
- Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 4
- Terminal elimination rate constant (λz)Time frame: Day 1 to Day 4
- Terminal elimination half-life (t½λz)Time frame: Day 1 to Day 4
- Apparent total body clearance (CL/F)Time frame: Day 1 to Day 4
- Non-renal clearance of drug from plasma (CLNR/F)Time frame: Day 1 to Day 4
- Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: Day 1 to Day 4
- Renal clearance of drug (CLR)Time frame: Day 1 to Day 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Sofia, Bulgaria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.